ELOX · Eloxx Pharmaceuticals, Inc.
The latest filing no longer states the doubt (first flagged May 5, 2026).
View the 10-Q filed Aug 11, 2026Price & Indicators
The closing range uses available history since Jun 9, 2026; less than a full year is stored.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ELOX
this stock
Eloxx Pharmaceuticals, Inc.
|
$77.86M | — | -100.0% | — | 0.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.72B | +20.7% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.89B | +5.6% | +20.8% | 20.2 | 2.3% |
|
ARGX
Argenx SE
|
$63.81B | +24.5% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$60.07B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 61.9%
- Net QoQ
- +2.5M sh
- Top holder
- EcoR1 Capital, LLC
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ELOX | +2.0% | +51.4% | — | +6.3% | — |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | +2.4% | +46.4% | — | +3.8% | — |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.